Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06898970 · ClinicalTrials.gov registry record · Phase 2
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
A Phase 2 study of Angiosarcoma and Angiosarcoma, Adult, sponsored by Varun Monga, MBBS.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06898970: Recruiting Phase 2 study of Angiosarcoma and Angiosarcoma, Adult, sponsored by Varun Monga, MBBS.
NCT06898970 is a Phase 2 study of Angiosarcoma and Angiosarcoma, Adult that is actively recruiting participants, run by Varun Monga, MBBS. The registered enrollment target is 18 participants, below the 1,092-participant average among 6 other Angiosarcoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06898970, a Phase 2 study of Angiosarcoma and Angiosarcoma, Adult, is actively recruiting participants, sponsored by Varun Monga, MBBS.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrolizumab for treating participants with angiosarcoma. This is the first study evaluating this novel combination in participants with advanced angiosarcoma who have progressed after prior immunotherapy.
Primary Outcome
Safety and tolerability will be reported as the percentage of the first 6 participants (the safety-lead in participants) who received at least one dose of study treatment with any reported treatment-emergent adverse events (TEAEs), \>= Grade 3 TEAEs, serious adverse events (SAEs), and TEAEs requiring discontinuation of VO. Adverse events will be classified using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- BIOLOGICAL Vusolimogene Oderparepvec (VO)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-01-09 |
| Est. Completion | 2029-10-31 |
| Phase | Phase 2 |
What NCT06898970 shows while recruiting
NCT06898970 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,092-participant average among 6 other Angiosarcoma trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Angiosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06898970 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06898970 about?
NCT06898970 is a clinical study titled "Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma". This is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrolizumab for treating participants with angiosarcoma. This is the first study evaluating this novel combination in participants with advanced a...
What is the current status of trial NCT06898970?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2026-01-09. Estimated completion is 2029-10-31.
What conditions does trial NCT06898970 study?
This clinical trial studies the following conditions: Angiosarcoma, Angiosarcoma, Adult.
What interventions are being tested in trial NCT06898970?
The interventions under investigation include: Pembrolizumab (DRUG), Vusolimogene Oderparepvec (VO) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06898970?
This trial is sponsored by Varun Monga, MBBS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06898970 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angiosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
RECRUITING · Phase 1
-
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI